Menu

BREAKING: Novo Nordisk Will Cease 340B Pricing for Hospital Contract Pharmacies on Jan. 1

In Breaking, Federal, Pharma Industry, RegulatoryDecember 1, 20200 Views

Novo Nordisk today joined Eli Lilly and Co., AstraZeneca, Sanofi, Novartis, and United Therapeutics in imposing conditions on provision of 340B pricing on products dispensed by contract pharmacies. Today’s announcement means all three U.S. domestic suppliers of insulin (Lilly, Sanofi, and Novo Nordisk) have adopted such policies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga